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OBJECTIVES: Articular cartilage is vulnerable to injuries and undergoes an irreversible degenerative process.
The use of amniotic fluid mesenchymal stromal stem cells for the reconstruction of articular cartilage is a
promising therapeutic alternative. The aim of this study was to investigate the chondrogenic potential of
amniotic fluid mesenchymal stromal stem cells from human amniotic fluid from second trimester pregnant
women in a micromass system (high-density cell culture) with TGF-b3 for 21 days.
METHODS:Micromass was performed using amniotic fluid mesenchymal stromal stem cells previously cultured in a
monolayer. Chondrocytes from adult human normal cartilage were used as controls. After 21 days, chondrogenic
potential was determined by measuring the expression of genes, such as SOX-9, type II collagen and aggrecan, in
newly differentiated cells by real-time PCR (qRT-PCR). The production of type II collagen protein was observed
by western blotting. Immunohistochemistry analysis was also performed to detect collagen type II and aggrecan.
This study was approved by the local ethics committee.
RESULTS: SOX-9, aggrecan and type II collagen were expressed in newly differentiated chondrocytes.
The expression of SOX-9 was significantly higher in newly differentiated chondrocytes than in adult cartilage.
Collagen type II protein was also detected.
CONCLUSION: We demonstrate that stem cells from human amniotic fluid are a suitable source for chondrogenesis
when cultured in a micromass system. amniotic fluid mesenchymal stromal stem cells are an extremely viable source
for clinical applications, and our results suggest the possibility of using human amniotic fluid as a source of
mesenchymal stem cells.
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’ INTRODUCTION
Chondrocytes represent the only cell type present in arti-
cular cartilage and are responsible for its homeostasis (1).
The cartilage extracellular matrix (ECM) is composed of a
network, including collagens, proteoglycans and other smal-
ler components. Collagen represents approximately 70-80%
of the dry tissue weight of cartilage and ensures its strength
and structural organization. Aggrecan is the second most
important component of the ECM, and it provides the
mechanical properties that allow cartilage to be compressed
(2). Cartilage is known for its limited ability to repair or
regenerate itself, which is due avascularity and a small
number of cells with low mitotic activity and metabolism.
Damage to cartilage may progress to osteoarthritis (OA),
which can cause clinically affected individuals to experience
pain and impair their joint function (3).
There have been numerous attempts to develop methods
to assist in cartilage repair (4). One of these methods is cell
therapy using high-density mobile systems (e.g., pellet or
micromass culture) to induce chondrogenesis, the initial stage
of cartilage formation (5). A previous study (6) reported that
mesenchymal stem cells (MSCs) have the capacity to induce
chondrocyte differentiation in pellet culture with serum-free
medium containing glucocorticoids and transforming growth
factor b (TGF-b).
For chondrogenesis, micromass culture provides a three-
dimensional environment that allows cell–cell interactions
similar to those during embryonic development; micromass
was first used to study endochondral skeletal development
in chicken embryos (7). Researchers (5) have compared the
chondrogenic potential of MSCs from bone marrow (BM)
in micromass or a pellet system and concluded that the
micromass system is more suitable for inducing chondro-
genesis. Our group studied chondrogenesis in MSCs fromDOI: 10.6061/clinics/2018/e268
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two different sources (periosteum-derived MSCs (8) and umbili-
cal cord blood (UCB) cells) and concluded that micromass
combined with TGF-b3 induces chondrogenesis in these two
different populations (9).
Additionally, during chondrogenesis, MSCs acquire a
spherical morphology and begin to express transcription
factors, such as Sox9 (10), Sox5 and Sox6, which regulate the
genes encoding type II collagen, aggrecan, and other compo-
nents of the ECM (11-13).
Other studies of horse MSCs from three different sources
(UCB, amniotic fluid (AF) and BM) found that mitotic
potential is greatest in MSCs collected from AF. Further-
more, these AF cells can be obtained from amniocentesis
waste, and the absence of HLA-DR cell-surface receptors
makes them immunologically advantageous for future
clinical applications (14).
SCs (from UCB and AF) have also been analyzed using
immunocytochemistry, and they express embryonic stem cell
antigens, such as Oct-4, SSEA-4 and TRA-1-60, indicating
pluripotency; moreover, SCs from AF likely represent an
intermediate stage between embryonic and adult SCs (15).
AF cells also express Tra-1-8 and the following germ layer
markers: FGF-5 (an ectodermal marker), AFP (an endoder-
mal marker) and Bra (a mesodermal marker). Injection of AF
cells into immunodeficient mice does not result in tumor
formation (16).
The aim of this work was to demonstrate that chondro-
genesis can be induced in amniotic fluid mesenchymal
stromal stem cells (AFMSCs) derived from pregnant women
during their second trimester using a micromass system in
the presence of TGF-b3 at both the gene expression and
protein levels.
’ MATERIALS AND METHODS
1. Collection of human amniotic fluid cells
After signing the informed consent form, 53 consecutive
women undergoing amniocentesis during their second
trimester of pregnancy allowed the collection of 30 ml of
their AF. Amniocentesis was suggested by amniocentesis
obstetrics upon suspicion of chromosomal abnormalities
according to the Fetal Medicine-specific protocol, Hospital
of Clinics, State University of Campinas (UNICAMP) (fetal
structural anomalies detected on ultrasound and increased
risk of chromosomal abnormalities by assessment of fetal
risk). Amniocentesis was performed using ultrasound.
The procedure was carried out as follows: the puncture
area was cleaned and isolated using a fenestrated field;
2% lidocaine was applied to both the surface of the skin
and subcutaneously without a vasoconstrictor; and the
amniotic cavity was accessed by abdominal puncture
using a 20G spinal needle for the withdrawal of 30 ml of
AF in two 20-ml syringes. Ten ml of AF was subsequently
sent to LABIMOCA (Laboratory of Molecular Biology
of Cartilage, Faculty of Medical Sciences, UNICAMP)
and cultured in 25 cm2 culture flasks containing 5 ml of
a-Minimum Essential Medium (a-MEM, Gibcot, USA)
with 20% fetal bovine serum (FBS, Gibcot BR) and
1% Pen/Strep (Gibcot USA). After 5 days, some AF cells
had adhered to the flask. The supernatant and non-adherent
cells were discarded, and the medium was replaced. At 70%
confluence, the cells were harvested by treatment with
0.25% trypsin/EDTA (Gibcot, Can) for 5 min at 37oC and
neutralized with 1% FBS.
The cells were washed twice with phosphate buffered
saline (PBS) and centrifuged at 300 g for 10 min.
SCs were obtained from residual cells. After a normal
karyotype result (performed in fetal medicine), approxi-
mately 5x104 cells were expanded in a 75 cm2 flask up to
70% confluence. The cells were then harvested, seeded in a
175 cm2 flask, and expanded up to 70% confluence. Next, we
split the cells into three 175 cm2 flasks and expanded them
up to 70% confluence. Samples with karyotype abnormalities
were discarded. From the initial 53 samples, 12 presented
normal karyotypes. Therefore, experiments were performed
with the 12 normal samples.
2. Characterization of amniotic fluid mesenchymal
stromal stem cells
In the fourth passage, some cells (approximately 1 to 3x105
per tube) were analyzed by flow cytometry for the expres-
sion of the following immunophenotypical markers: CD73,
CD90, CD105, CD14, CD19, CD34, CD-45, HLA-DR, CD44,
CD49c, CD151, SSEA-4, OCT-4, NANOG and CD117
(Biolegendt, USA and BD Pharmingent). The cells were
analyzed on a BD FACSCantot cytofluorometer using BD
FACSDivat software (Becton, Dickson and Company, USA).
During the same passage, pluripotency was assessed by
plastic adherence (Olympus inverted optical microscope), as
well as adipogenic, osteogenic and chondrogenic differentia-
tion (17) by Stem Prot (Gibco, USA), according to the manu-
facturer’s protocol.
3. Differentiation
Cells were divided into 50 samples (each containing
approximately 5x105 cells in a 20-ml volume) and placed
into 96-well V-bottom culture plates. The cells were incu-
bated at 37oC with 5% CO2 for 2 h to create micromass
cultures. Next, medium was added without cell spreading.
Differentiation was carried out using Dulbecco’s Modified
Eagle’s Medium (DMEM) supplemented with high glucose
(Life Sciences), 10 ng/ml TGF-b3 (R&D Systems), 100 nM
dexamethasone, 1x Insulin-transferrin-sodium selenite, lino-
leic-BSA (ITS+1) premix, 40 mg/ml proline, and 50 mg/ml
ascorbic acid (Sigma-Aldrich, Poole, UK, http://www.
sigmaaldrich.com). The cells remained in micromass culture
for 21 days.
4. Confirmation of chondrocyte differentiation
4.1. Histologic analysis. Histologic analysis of chondro-
genesis was performed by hematoxylin-eosin (HE); Masson’s
trichrome (MT) and picrosirius red (PR) were used for
collagen-specific staining; and Alcian blue (AB) was used for
proteoglycans. Immunochemistry analysis was performed
using a rabbit polyclonal antibody (1:100, BIOSSt-USA, bs-
0709R) for collagen type II and a rabbit polyclonal antibody
(1:100, BIOSSt, USA, bs-11655R) for aggrecan; immunoche-
mistry was performed as previously described by others (18).
4.2. qRT-PCR: real-time quantitative polymerase chain
reaction after reverse transcription. Chondrocyte differ-
entiation was also confirmed by qRT-PCR. RNA was extrac-
ted using TRIzolt remove contaminating genomic DNA.
RNA was subsequently reverse transcribed to obtain cDNA
using SuperScript IIt reverse transcriptase (Invitrogen).
Quantitative PCR (real-time) was performed using the SYBR
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green method with a Stratagene Mx 3000P machine. For the
genes type II collagen, aggrecan, SOX-9 and GAPDH, primers
were designed from genomic libraries using the ABI Primer
Expresst program (Applied Biosystems, USA). Each experi-
ment was performed in triplicate. The primer sequences are
listed in Table 1.
The total volume (12 ml) of each PCR reaction contained
6 ml SYBR Green PCR Master Mix, 10 ng cDNA (3 ml) and
150 pM (3 ml) of each forward and reverse primer. Real-time
PCR reactions were performed under the following condi-
tions: 95oC for 10 min (activation), 45 cycles of 95oC for 15 s,
60oC for 20 s, 72oC for 20 s (amplification), and 72oC for 1 min
(final extension). Melting curves were examined after PCR was
completed to confirm the specificity of the amplified products.
Real-time PCR reactions were carried out with templates from
MSCs without treatment (TO), MSCs under micromass condi-
tions for 21 days with TGF-b3 (A1) and chondrocytes obtained
from human adult articular cartilage (chondro).
5. Western blotting
Proteins secreted by cells into the medium during 21 days
of micromass culture were precipitated by 2 mg/ml pepsin
(Sigma-Aldrich, USA). The samples were incubated at 30oC
for 30 min, stored overnight at 4oC with stirring, and centri-
fuged for 90 min at 2300 g. The pellets were washed twice
with PBS. Protein was quantified using Bradford’s method.
Thirty mg of protein was separated on a 10% sodium
dodecyl sulfate polyacrylamide (SDS-PAGE) gel and handled
according to the protocol followed by our laboratory (8,9)
using a rabbit collagen II polyclonal antibody (1:500, BIOSSt,
USA). Signals were visualized using a Super Signal West
Pico Chemiluminescent Substrate Kit (Super Signal West Pico
Stable Peroxide Solution, 500 ml; and Super Signal West Pico
Luminol Enhancer Solution, 500 ml; Thermo Scientific Pierce
Protein Products Researcht).
6. Statistical analysis
Statistical analyses were carried out using one-way ana-
lysis of variance (ANOVA) with GraphPad Prism software.
The confidence interval was 95% considering the multiple
comparisons between groups. The results were considered
significant at po0.05.
’ RESULTS
1. Amniotic fluid stem cell characterization
Immunophenotypic characterization by flow cytometry
revealed that MSCs from human amniotic fluid (HAF) were
positive for mesenchymal markers CD90 (63.3%), CD73
(99.5%), and CD105 (22.7%). MSCs were negative for the
hematopoietic markers CD14 (4.9%), CD45 (3.5%), CD19
(4.3%), HLA-DR (0.7%) and CD 34 (3.3%). The following
pluripotency markers investigated in this study were positive:
SSEA-4 (92.3%), NANOG (79.4%), OCT4 (98.8%) and CD117
(14.2%). The chondrogenic potency markers CD49c (99.8%),
CD44 (99.9%) and CD151 (99%) were also positive (Figure 1).
Moreover, using Stem Pro (Gibco, NY), we observed plastic
fixation (Figure 2) of AFMSCs, as well as osteogenic, adipo-
genic and chondrogenic differentiation (Figure 3).
2. Histology
Micromasses were fixed in 4% buffered formalin and
rinsed twice in PBS. Next, the micromasses were processed
and embedded in paraffin. After preparation, 5-mm-thick
sections were stained with HE, MT, PR and AB. The results
are shown in Figure 4. HE shows the production of cartilage
matrix in pinkish and bluish staining (high amount of pro-
teoglycans), and cell nuclei appear in blue. Collagen pro-
duction is shown by MT in blue staining that permeated all
the sections in red; the cells contained black nuclei. In PR-
stained sections, collagen appears pale yellow to light brown;
when several collagen fibers aggregate, they appear red.
Glycosaminoglycans (GAGs) appear light blue with AB
staining.
3. Real-time PCR (qRT-PCR)
We confirmed the expression of cartilage-specific genes in
differentiated cells. Figure 5A shows that the expression of
SOX9 in cells subjected to micromass culture for 21 days with
TGF-b3 (A1) was significantly higher than that in cells in
monolayer culture without TGF-b3 (TO) and normal human
articular cartilage (chondro) (po0.05). The expression of type
II collagen in cells subjected to micromass culture for 21 days
with TGF-b3 (A1) (Figure 5B) was higher than that in cells in
monolayer culture without TGF-b3 (TO), which were used as
a negative control, and lower than that in normal human
articular cartilage (chondro), which was used as a positive
control. Figure 5C shows that the expression of aggrecan in
cells during micromass culture for 21 days with TGF-b3 (A1)
was higher than that in cells in monolayer culture without
TGF-b3 (TO; negative control) and lower than that in normal
human articular cartilage (chondro; the positive control).
4. Western blotting
As shown in Figure 4, collagen type II, which is very
specific to articular cartilage chondrocytes, was produced
and secreted by cells into the medium during micromass
culture in the presence of TGF-b3 for 21 days. Collagen type
II was detected in pooled medium (Figure 6).
5. Immunohistochemistry
In Figure 7, immunohistochemical staining for both col-
lagen type II and aggrecan is shown and compared with
negative staining.
’ DISCUSSION
Articular cartilage has a limited capacity to recover from
trauma. There have been numerous attempts to protect and/
or rehabilitate injured cartilage tissue, but these medical
procedures do not guarantee its regeneration. The methods
used to correct problems with cartilage include microfrac-
ture, chondroplasty, osteochondral grafts (19,20), abrasion
arthroplasty (13) and autologous chondrocyte implantation
(ACI), a surgical procedure widely used to regenerate arti-
cular cartilage (21). However, despite the new materials
currently available, ACI has certain disadvantages, including
Table 1 - Sequences of primers used in qRT-PCR reactions were
designed using the ABI Primer Express program (Applied
Biosystems, USA).
Collagen II Forward GGCAATAGCAGGTTCACGTACA
Collagen II Reverse CGATAACAGTCTTGCCCCACTT
Aggrecan Forward TCGAGGACAGCGAGGCC
Aggrecan Reverse TCGAGGGTGTAGCGTGTAGAGA
GAPDH Forward GCACCGTCAAGGCTGAGAAC
GAPDH Reverse CCACTTGATTTTGGAGGGATCT
3
CLINICS 2018;73:e268 Human amniotic stem cells and chondrogenesis
Zuliani CC et al.
the possibility of chondrocyte leakage and death, as well as
the potential for fibrocartilage production in some patients
(22). Compared with other therapies, therapy using MSCs
derived from human AF is a promising new treatment
because it has great potential for tissue recovery, given the
chondrogenic potential and pluripotency of these SCs (16).
In the present study, the immunophenotypic characteriza-
tion of MSCs from HAF was slightly different from that of
MSCs from other sources. This difference is likely due to the
high variability of cell lineages present in AF, which has been
observed by others (23,24).
We studied the effects of micromass culture on MSCs
derived from human AF over a period of 21 days. We chose
to study the micromass system because previous studies (5)
have shown that compared with the pellet system, this
system yields a higher sulfate GAG (sGAG) deposition rate
and higher overall dry weight. In micromass systems, new
cells appear to be more homogeneous, and apoptosis is lower
in these cells than in cells differentiated using the pellet
system. Finally, the expression of type II collagen is
significantly higher than that of type X and type I collagen,
which are indicators of fibrocartilage. Thus, the micromass
culture system appears to be the most suitable for inducing
chondrogenesis (5). The results we observed are similar
to those previously described, despite the fact that we
observed the protein expression of type II collagen on day
21 (using western blotting), while previous studies repor-
ted collagen production on day 14 (using immunohisto-
chemical techniques). This discrepancy might be related to
differences in study design. Additionally, qRT-PCR revea-
led elevated expression of type II collagen, which was
consistent with chondrogenesis. Conversely, type II col-
lagen gene expression was not detected using cDNA from
AFMSCs without differentiation. For the first time, we also
compared the expression of type II collagen in ‘‘newborn’’
cells with that in normal human adult cartilage, and we
confirmed similar expression levels between the two cell
populations. By contrast, type II collagen expression was
Figure 1 - Flow cytometry analysis of the AFMSC pluripotency profile in samples at the third passage after harvesting. The percentage of
each marker is shown in the upper right corner in the graphs.
Figure 2 - Adherent AFMSCs on plastic showing fibroblast-like
morphology after 10 days in culture (400X).
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not observed in AFMSCs that had not undergone differ-
entiation. This finding reinforces the fact that the micromass
system provides an efficient method for inducing chondrogen-
esis. Our evidence also complements the findings of another
study (5) in which the authors examined the expression of
SOX-9 and aggrecan up to day 14. We continued culturing
cells until day 21 and analyzed the gene expression of SOX-9
and aggrecan; moreover, we measured the levels of these
Figure 4 - Histological analysis: A) Macroscopic aspect of micromasses after 21 days in TGF-b3-stimulated culture; B and C) The
production of cartilage matrix is shown in pinkish and bluish staining (high amount of proteoglycans), and cell nuclei are shown in blue
by HE; D and E) GAGs are shown in light blue by AB, and collagen production is shown in blue staining that permeated all the sections
in red by MT; the cells contained black nuclei; F and G) In PR-stained sections, collagen appears pale yellow but becomes red when
collagen fibers aggregate; H and I) In MT-stained sections, collagen production appears in blue staining that permeated all the sections
in red; the cells contained black nuclei.
Figure 3 - Capacity to differentiate: A) Osteogenic differentiation on plastic shown after staining with Alizarin red; B) Chondrogenic
differentiation after staining with Alcian blue; C) Adipogenic differentiation shown by oil red O.
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genes in normal human adult cartilage, which yielded results
that are more relevant to human physiology.
When chondrogenesis is induced in AFMSCs using the
pellet system technique, the expression of type II collagen is
higher in cells treated with TGF- b3 than in cells treated with
TGF-b1 or TGF-b2 (25). Interestingly, cells treated with TGF-
b1 produce significantly higher amounts of sGAG than do
cells supplemented with TGF-b3 (26). However, the expres-
sion of sGAG is higher in AFMSCs stimulated with TGF-b3
or TGF-b2 and dexamethasone than in those stimulated with
dexamethasone and TGF-b1. Thus, TGF-b3 appears to be
superior to TGF-b1 (25). Our decision to use TGF-b3 was also
based on a previous study from our group in which TGF-b3
was more efficient for inducing differentiation of MSCs
derived from UCB into chondrocytes (9) than other growth
factors (TGF-b3 was combined with dexamethasone to induce
chondrogenesis). As a result, we were able to successfully
induce the expression of type II collagen, aggrecan and SOX-9.
In this study, chondrogenesis was induced in HAF-derived
MSCs stimulated with TGF-b3 over 21 days using the micro-
mass system. We confirmed this differentiation by analyzing
the expression of the most important genes for the formation
of articular cartilage (SOX-9, collagen type II and aggrecan)
and confirmed the production of collagen type II at the
protein level using histology or western blotting. Compared
with normal human cartilage (used as a standard), cells under
the micromass system showed significantly higher expression
of the SOX-9 gene, as depicted in Figure 3A. This result
indicates that it is possible to reproduce human chondrogen-
esis in vitro, as SOX-9 is a key factor in inducing this process.
Our results are reinforced by another study (5) in which the
authors detected SOX-9 expression in cells under the micro-
mass system but did not find a significant difference compared
with that in cells under the pellet system, thereby indicating
that transcription factor SOX-9 is essential for inducing
chondrogenesis in both high-density systems.
Furthermore, Arnhold S et al. (27,28) demonstrated that
HAF contains a heterogeneous cell population composed of
Figure 5 - qRT-PCR: T0 represents the negative control for AFMSC gene expression; A1: Newly differentiated cell gene expression;
chondro represents adult human articular chondrocytes as a positive control. A) SOX-9 expression is higher in young cells than in adult
cells. B) and C) Type II collagen and aggrecan are expressed in new cells but not in AFMSCs, confirming that differentiation occurred.
Figure 6 -Western blotting showing positivity for collagen type II
in culture medium with TGF-b3 after 21 days.
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many cell types, including fibroblast cells with the capacity
to differentiate into osteogenic, adipogenic, and chondrogenic
lineages; epithelial cells; and cell types that could become
other cell lineages. Thus, this source of SCs can potentially be
applied to diseases of osteogenic and chondrogenic lineages,
as well as neurodegenerative diseases, such as retinopathy of
prematurity.
Our results support advancement from preclinical to clinical
research targeting the implantation of new chondrocytes dif-
ferentiated from AFMSCs under the micromass culture system
in cartilage lesions. Moreover, our findings support the use
of newly differentiated chondrocytes on scaffolds in future
studies.
This novel combination of MSCs derived from HAF using
the micromass culture system and TGF-b3 over a period of
21 days demonstrates an increase in chondrogenesis and the
induction of the expression of SOX-9, collagen type II and
aggrecan.
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